Skip to main content

Celebrating 20 years of BMC Cancer


New Content Item (1)BMC Cancer is celebrating its twentieth anniversary! 

Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all.

We're looking back at our achievements and highlighting some of the most influential research published in the journal over the past two decades. We hope you join us in marking this occasion and that you consider submitting your next manuscript to BMC Cancer.

A look back at our milestones

Explore major milestones from throughout BMC Cancer's history. 

New Content Item

20 articles for 20 years

We have put together a list of twenty of our most accessed and interesting articles over the last two decades. While this list is by no means exhaustive, we hope you enjoy looking back at how far the field of cancer research has come.
 

Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study
Iris D Nagtegaal, Corrie AM Marijnen, Elma Klein Kranenbarg, Adri Mulder-Stapel, Jo Hermans, Cornelis JH van de Velde & J Han JM van Krieken 
BMC Cancer 1, 7 (2001)

Regular aspirin use and lung cancer risk
Kirsten B Moysich, Ravi J Menezes, Adrienne Ronsani, Helen Swede, Mary E Reid, K Michael Cummings, Karen L Falkner, Gregory M Loewen & Gerold Bepler 
BMC Cancer 2, 31 (2002)

Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells
Liza Konnikova, Maciej Kotecki, Mathew M Kruger & Brent H Cochran 
BMC Cancer 3, 23 (2003)

CD155/PVR plays a key role in cell motility during tumor cell invasion and migration
Kevin E Sloan, Brenda K Eustace, Jean K Stewart, Carol Zehetmeier, Claudia Torella, Marina Simeone, Jennifer E Roy, Christine Unger, David N Louis, Leodevico L Ilag & Daniel G Jay 
BMC Cancer 4, 73 (2004)

Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer
Daniela Thorwarth, Susanne-Martina Eschmann, Jutta Scheiderbauer, Frank Paulsen & Markus Alber 
BMC Cancer 5, 152 (2005)

The claudin gene family: expression in normal and neoplastic tissues
Kyle J Hewitt, Rachana Agarwal & Patrice J Morin 
BMC Cancer 6, 186 (2006)

Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process
Uma R Chandran, Changqing Ma, Rajiv Dhir, Michelle Bisceglia, Maureen Lyons-Weiler, Wenjing Liang, George Michalopoulos, Michael Becich & Federico A Monzon 
BMC Cancer 7, 64 (2007)

Imagable 4T1 model for the study of late stage breast cancer
Kai Tao, Min Fang, Joseph Alroy & G Gary Sahagian
BMC Cancer 8, 228 (2008)

Noninvasive detection of lung cancer by analysis of exhaled breath
Amel Bajtarevic, Clemens Ager, Martin Pienz, Martin Klieber, Konrad Schwarz, Magdalena Ligor, Tomasz Ligor, Wojciech Filipiak, Hubert Denz, Michael Fiegl, Wolfgang Hilbe, Wolfgang Weiss, Peter Lukas, Herbert Jamnig, Martin Hackl, Alfred Haidenberger, Bogusław Buszewski, Wolfram Miekisch, Jochen Schubert & Anton Amann
BMC Cancer 9, 348 (2009)

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials 
Lesley A Smith, Victoria R Cornelius, Christopher J Plummer, Gill Levitt, Mark Verrill, Peter Canney & Alison Jones 
BMC Cancer 10, 337 (2010)

Interaction and uptake of exosomes by ovarian cancer cell 
Cristina Escrevente, Sascha Keller, Peter Altevogt & Júlia Costa
BMC Cancer 11, 108 (2011)

Hypoxic enhancement of exosome release by breast cancer cells 
Hamish W King, Michael Z Michael & Jonathan M Gleadle
BMC Cancer 12, 421 (2012)

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing 
Paola Longati, Xiaohui Jia, Johannes Eimer, Annika Wagman, Michael-Robin Witt, Stefan Rehnmark, Caroline Verbeke, Rune Toftgård, Matthias Löhr & Rainer L Heuchel
BMC Cancer 13, 95 (2013) 

Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition 
Gaofeng Xiong, Lei Deng, Jieqing Zhu, Piotr G Rychahou & Ren Xu 
BMC Cancer 14, 1 (2014) 

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management 
J. Joshua Smith, Oliver S. Chow, Marc J. Gollub, Garrett M. Nash, Larissa K. Temple, Martin R. Weiser, José G. Guillem, Philip B. Paty, Karin Avila & Julio Garcia-Aguilar on behalf of the Rectal Cancer Consortium 
BMC Cancer 15, 767 (2015) 

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) 
Jens Hoeppner, Florian Lordick, Thomas Brunner, Torben Glatz, Peter Bronsert, Nadine Röthling, Claudia Schmoor, Dietmar Lorenz, Christian Ell, Ulrich T. Hopt & J. Rüdiger Siewert 
BMC Cancer 16, 503 (2016) 

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study 
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf & Axel Hauschild for the ERIVANCE BCC Investigators
BMC Cancer 17, 332 (2017) 

Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins 
Carrie J. Lovitt, Todd B. Shelper & Vicky M. Avery
BMC Cancer 18, 41 (2018) 

Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation 
Stefanus van Rooijen, Francesco Carli, Susanne Dalton, Gwendolyn Thomas, Rasmus Bojesen, Morgan Le Guen, Nicolas Barizien, Rashami Awasthi, Enrico Minnella, Sandra Beijer, Graciela Martínez-Palli, Rianne van Lieshout, Ismayil Gögenur, Carlo Feo, Christoffer Johansen, Celena Scheede-Bergdahl, Rudi Roumen, Goof Schep & Gerrit Slooter 
BMC Cancer 19, 98 (2019)

A convolutional neural network-based system to classify patients using FDG PET/CT examinations 
Keisuke Kawauchi, Sho Furuya, Kenji Hirata, Chietsugu Katoh, Osamu Manabe, Kentaro Kobayashi, Shiro Watanabe & Tohru Shiga 
BMC Cancer 20, 227 (2020)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar & Roman Hajek 
BMC Cancer 21, 73 (2021)





Annual Journal Metrics

  • Speed
    79 days to first decision for reviewed manuscripts only
    55 days to first decision for all manuscripts
    170 days from submission to acceptance
    16 days from acceptance to publication

    Citation Impact
    4.430 - 2-year Impact Factor
    4.372 - 5-year Impact Factor
    1.218 - Source Normalized Impact per Paper (SNIP)
    1.358 - SCImago Journal Rank (SJR)

    Usage 
    5,089,371 Downloads
    2,117 Altmetric Mentions